Patients/ Views & Analysis/ Views and analysis ‘Build back better’ cannot mean longer waiting times for change mike.hammerton@pharmaphorum.com Global Blood Therapeutics, Nigel Nicholls, sickle cell disease 0 Comment Global Blood Therapeutics (GBT) UK general manager Nigel Nicholls discusses the impact of COVID-19 for sickle cell patients Share X ‘Build back better’ cannot mean longer waiting times for change https://pharmaphorum.com/patients/covid-sickle-cell-nhs-impact/